Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

The following article, which first appeared in The Post-Journal in May 2014, is an example of why there can more to a story ...

The following article, which first saw the light of day in May 2014, is an example of why there can more to a story than ...

KUALA LUMPUR, Malaysia, Feb. 25, 2025 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, announced that ...

A family is preparing for three fundraising challenges in memory of their husband and dad who received treatment at an Oxford hospital.

Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Samsung Bioepis announced FDA approval of Ospomyv and Xbryk, biosimilars referencing denosumab (Prolia, Xgeva).

The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

Read about the creation of a guide to sexual intimacy for people with stomas, led by specialist stoma nurse Kyle Waring.

"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...